pennsylvaniauniversitycancerScientist Carl June will share $3 million for his success in using a patient’s own immune system to fight cancer with Michel Saidelen, another researcher who also made a breakthrough in treating cancer. “Breakthrough Award”.
The “Breakthrough Award” is an annual award sponsored by technology industry giants to appreciate researchers who have made breakthroughs in science, medical care, mathematics, etc. Each prize is worth NT$3 million. The list of this year’s winners has been announced in a few days before and is scheduled to be held in April next year. The awards ceremony will be held in Los Angeles on the 13th.
Jun pioneered a genetically engineered cancer treatment technique called CAR-T at the University of Pennsylvania 13 years ago. This technology has now treated more than 20,000 patients with leukemia and other deadly blood cancers, with a success rate between 50% and 90%.
Another Sadran who shared the prize money was at New York Sloan around the same time –catMemorial Sloan Kettering Cancer Center is developing similar technology.
In the mid-1990s, some scientists such as Zhu En and Sudran were studying how to enhance the anti-cancer ability of T cells (T in CAR-T) in the immune system of cancer patients. The principle is to remove T cells from the patient’s blood, genetically modify them to make their own anti-cancer drugs, and re-inject them into the body.
The treatment developed in June’s laboratory later became Kymriah, a leukemia drug manufactured by Novartis, which was approved by the federal Food and Drug Administration (FDA) in 2017. Five CAR-T drugs have since been released.
After announcing the winners, June said she is grateful for the award, but the most valuable thing is seeing it go global and benefiting so many people.
Penn arrived in June 1999 and is still studying the modification of T cells to fight other types of cancer. Additionally, he is also studying whether this concept of modifying cells can fight non-cancer diseases, including heart failure, lupus erythematosus, etc. Autoimmune diseases.
To address these challenges, he is trying to combine the CAR-T approach with another popular pen technology, messenger RNA, which is the basis of the Pfizer and Moderna COVID-19 vaccines.